File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of rivastigmine in the treatment of behavioural and psychological symptoms in Chinese dementia patients: An open-label study

TitleEfficacy and safety of rivastigmine in the treatment of behavioural and psychological symptoms in Chinese dementia patients: An open-label study
Authors
KeywordsAlzheimer Disease
Behavioral Symptoms
Cholinesterase Inhibitors
Issue Date2006
PublisherHong Kong College of Psychiatrists. The Journal's web site is located at http://www.hkjpsych.com/search.jsp
Citation
Hong Kong Journal Of Psychiatry, 2006, v. 16 n. 3, p. 101-108 How to Cite?
AbstractObjectives: Behavioural and psychological symptoms of dementia are integral features of Alzheimer's disease. They have been recognised as important predictors for premature institutionalisation and constitute major caregiver burdens. This study examined the efficacy of rivastigmine in the treatment of behavioural and psychological symptoms of dementia in Chinese older adults suffering from mild-to-moderately severe Alzheimer's disease, under conditions reflecting everyday clinical care. Rivastigmine tolerability and its effects on cognition and functional status were also assessed. Patients and Methods: This was a 20-week prospective, open-label, single-centre study. Twenty four psychogeriatric outpatients, who fulfilled DSM-IV diagnosis criteria for Dementia of the Alzheimer's Type and exhibited behavioural and psychological symptoms of dementia, were treated with flexible doses of rivastigmine. Clinical responses were evaluated using the Chinese version of the Neuropsychiatric Inventory (CNPI), the Cantonese version of the Mini-Mental State Examination (CMMSE), and Functional Assessment Staging (FAST). Results: At week 20, the mean CNPI total score decreased by 19.5 (p < 0.001) with significant improvements regarding delusions, depression / dysphoria, apathy, disinhibition, irritability / lability, aberrant motor behaviour, and night-time behaviour disturbance. Clinically significant reductions in behavioural and psychological symptoms of dementia were observed in 20 (83%) of the patients. The percentage change in CNPI total score correlated with percentage change in CNPI caregiver distress score (Spearman's rho = 0.8, p < 0.001), but not with the rivastigmine dosage (Spearman's rho = 0.004, p = 0.99) or change in CMMSE score (Spearman's rho = -0.175, p = 0.41). No significant changes in CMMSE and FAST scores were demonstrated. The mean ± SD daily dose of rivastigmine was 9 ± 3 mg. Rivastigmine was well-tolerated in general, though a significant mean weight loss of 2 kg (p < 0.001) was noted. Conclusion: This study suggested that rivastigmine was well-tolerated and effective in improving behavioural and psychological symptoms of dementia in Chinese patients with mild-to-moderately severe Alzheimer's disease. Its beneficial effect on behavioural and psychological symptoms of dementia was independent of dosage and cognitive response. More rigorous investigations are needed to confirm and clarify the potential therapeutic role of the drug in ameliorating behavioural and psychological symptoms of dementia. © 2006 Hong Kong College of Psychiatrists.
Persistent Identifierhttp://hdl.handle.net/10722/174237
ISSN
2012 SCImago Journal Rankings: 0.158
References

 

DC FieldValueLanguage
dc.contributor.authorChan, CFen_US
dc.contributor.authorChan, WCen_US
dc.contributor.authorLi, SWen_US
dc.date.accessioned2012-11-22T02:01:27Z-
dc.date.available2012-11-22T02:01:27Z-
dc.date.issued2006en_US
dc.identifier.citationHong Kong Journal Of Psychiatry, 2006, v. 16 n. 3, p. 101-108en_US
dc.identifier.issn1026-2121en_US
dc.identifier.urihttp://hdl.handle.net/10722/174237-
dc.description.abstractObjectives: Behavioural and psychological symptoms of dementia are integral features of Alzheimer's disease. They have been recognised as important predictors for premature institutionalisation and constitute major caregiver burdens. This study examined the efficacy of rivastigmine in the treatment of behavioural and psychological symptoms of dementia in Chinese older adults suffering from mild-to-moderately severe Alzheimer's disease, under conditions reflecting everyday clinical care. Rivastigmine tolerability and its effects on cognition and functional status were also assessed. Patients and Methods: This was a 20-week prospective, open-label, single-centre study. Twenty four psychogeriatric outpatients, who fulfilled DSM-IV diagnosis criteria for Dementia of the Alzheimer's Type and exhibited behavioural and psychological symptoms of dementia, were treated with flexible doses of rivastigmine. Clinical responses were evaluated using the Chinese version of the Neuropsychiatric Inventory (CNPI), the Cantonese version of the Mini-Mental State Examination (CMMSE), and Functional Assessment Staging (FAST). Results: At week 20, the mean CNPI total score decreased by 19.5 (p < 0.001) with significant improvements regarding delusions, depression / dysphoria, apathy, disinhibition, irritability / lability, aberrant motor behaviour, and night-time behaviour disturbance. Clinically significant reductions in behavioural and psychological symptoms of dementia were observed in 20 (83%) of the patients. The percentage change in CNPI total score correlated with percentage change in CNPI caregiver distress score (Spearman's rho = 0.8, p < 0.001), but not with the rivastigmine dosage (Spearman's rho = 0.004, p = 0.99) or change in CMMSE score (Spearman's rho = -0.175, p = 0.41). No significant changes in CMMSE and FAST scores were demonstrated. The mean ± SD daily dose of rivastigmine was 9 ± 3 mg. Rivastigmine was well-tolerated in general, though a significant mean weight loss of 2 kg (p < 0.001) was noted. Conclusion: This study suggested that rivastigmine was well-tolerated and effective in improving behavioural and psychological symptoms of dementia in Chinese patients with mild-to-moderately severe Alzheimer's disease. Its beneficial effect on behavioural and psychological symptoms of dementia was independent of dosage and cognitive response. More rigorous investigations are needed to confirm and clarify the potential therapeutic role of the drug in ameliorating behavioural and psychological symptoms of dementia. © 2006 Hong Kong College of Psychiatrists.en_US
dc.languageengen_US
dc.publisherHong Kong College of Psychiatrists. The Journal's web site is located at http://www.hkjpsych.com/search.jspen_US
dc.relation.ispartofHong Kong Journal of Psychiatryen_US
dc.subjectAlzheimer Diseaseen_US
dc.subjectBehavioral Symptomsen_US
dc.subjectCholinesterase Inhibitorsen_US
dc.titleEfficacy and safety of rivastigmine in the treatment of behavioural and psychological symptoms in Chinese dementia patients: An open-label studyen_US
dc.typeArticleen_US
dc.identifier.emailChan, WC: waicchan@hku.hken_US
dc.identifier.authorityChan, WC=rp01687en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-35349023229en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-35349023229&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue3en_US
dc.identifier.spage101en_US
dc.identifier.epage108en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridChan, CF=22933358100en_US
dc.identifier.scopusauthoridChan, WC=16400525900en_US
dc.identifier.scopusauthoridLi, SW=7409240495en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats